Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy

por Gerritsen, Winald R., Sharma, Padmanee
Publicado 2011

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

por Siddiqui, Bilal A., Subudhi, Sumit K., Sharma, Padmanee
Publicado 2022

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies

por Michielin, Olivier, Lalani, Aly-Khan, Robert, Caroline, Sharma, Padmanee, Peters, Solange
Publicado 2022

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

por Fan, Xiaozhou, Quezada, Sergio A., Sepulveda, Manuel A., Sharma, Padmanee, Allison, James P.
Publicado 2014

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy

por Hailemichael, Yared, Fu, Tihui, Khong, Hiep, Dai, Zhimin, Sharma, Padmanee, Overwijk, Willem W
Publicado 2014

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer

por Raval, Raju R, Sharabi, Andrew B, Walker, Amanda J, Drake, Charles G, Sharma, Padmanee
Publicado 2014

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

por Bilen, Mehmet Asim, Subudhi, Sumit K., Gao, Jianjun, Tannir, Nizar M., Tu, Shi-Ming, Sharma, Padmanee
Publicado 2016

Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience

por Gao, Jianjun, He, Qiuming, Subudhi, Sumit, Aparicio, Ana, Zurita-Saavedra, Amado, Lee, Da Hyun, Jimenez, Camilo, Suarez-Almazor, Maria, Sharma, Padmanee
Publicado 2015

A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent

por Sharma, Padmanee, Grimm, Marc-Oliver, Galsky, Matthew D, Baron, Ari, Bracarda, Sergio, Siefker-Radtke, Arlene, Lambert, Alexandre, Azrilevich, Alex, Retz, Margitta
Publicado 2015

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

por Zamarin, Dmitriy, Holmgaard, Rikke B., Ricca, Jacob, Plitt, Tamar, Palese, Peter, Sharma, Padmanee, Merghoub, Taha, Wolchok, Jedd D., Allison, James P.
Publicado 2017

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

por Shi, Lewis Zhichang, Fu, Tihui, Guan, Baoxiang, Chen, Jianfeng, Blando, Jorge M., Allison, James P., Xiong, Liangwen, Subudhi, Sumit K., Gao, Jianjun, Sharma, Padmanee
Publicado 2016

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021

por Burton, Elizabeth M., Amaria, Rodabe N., Cascone, Tina, Chalabi, Myriam, Gross, Neil D., Mittendorf, Elizabeth A., Scolyer, Richard A., Sharma, Padmanee, Ascierto, Paolo A.
Publicado 2022

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case...

por Uemura, Marc, Trinh, Van A., Haymaker, Cara, Jackson, Natalie, Kim, Dae Won, Allison, James P., Sharma, Padmanee, Vence, Luis, Bernatchez, Chantale, Hwu, Patrick, Diab, Adi
Publicado 2016

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

por Page, David B., Bourla, Ariel Bulua, Daniyan, Anthony, Naidoo, Jarushka, Smith, Eric, Smith, Melody, Friedman, Claire, Khalil, Danny N., Funt, Samuel, Shoushtari, Alexander N., Overwijk, Willem W., Sharma, Padmanee, Callahan, Margaret K.
Publicado 2015

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune su...

por Subudhi, Sumit K, Siddiqui, Bilal A, Aparicio, Ana M, Yadav, Shalini S, Basu, Sreyashi, Chen, Hong, Jindal, Sonali, Tidwell, Rebecca S S, Varma, Ashwin, Logothetis, Christopher J, Allison, James P, Corn, Paul G, Sharma, Padmanee
Publicado 2021

Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer

por Subudhi, Sumit K, Aparicio, Ana, Gao, Jianjun, Zurita, Amado, John, Araujo, Logothetis, Christopher, Rao, Brinda, Vence, Luis, Allison, James, Emerson, Ryan O, Yusko, Erik, Vignali, Marissa, Robins, Harlan, Sun, Jing Jing, Sharma, Padmanee
Publicado 2015

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer

por Lu, Xin, Horner, James W., Paul, Erin, Shang, Xiaoying, Troncoso, Patricia, Deng, Pingna, Jiang, Shan, Chang, Qing, Spring, Denise J., Sharma, Padmanee, Zebala, John A., Maeda, Dean Y., Wang, Y. Alan, DePinho, Ronald A.
Publicado 2017

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

por Janjigian, Yelena Y., Bendell, Johanna, Calvo, Emiliano, Kim, Joseph W., Ascierto, Paolo A., Sharma, Padmanee, Ott, Patrick A., Peltola, Katriina, Jaeger, Dirk, Evans, Jeffry, de Braud, Filippo, Chau, Ian, Harbison, Christopher T., Dorange, Cecile, Tschaika, Marina, Le, Dung T.
Publicado 2018

High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer

por Massarelli, Erminia, Lam, Vincent K., Parra, Edwin R., Rodriguez-Canales, Jaime, Behrens, Carmen, Diao, Lixia, Wang, Jing, Blando, Jorge, Byers, Lauren A., Yanamandra, Niranjan, Brett, Sara, Morley, Peter, Sharma, Padmanee, Allison, James, Wistuba, Ignacio I., Heymach, John V.
Publicado 2019

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer

por Sinha, Meenal, Zhang, Li, Subudhi, Sumit, Chen, Brandon, Marquez, Jaqueline, Liu, Eric V, Allaire, Kate, Cheung, Alexander, Ng, Sharon, Nguyen, Christopher, Friedlander, Terence W, Aggarwal, Rahul, Spitzer, Matthew, Allison, James P, Small, Eric J, Sharma, Padmanee, Fong, Lawrence
Publicado 2021